February 19, 2011 -- Bayer plans to double the research staff at its Beijing drug R&D center; Charles River Labs wants to sell its Shanghai pre-clinical drug development lab and is talking with potential buyers; the Chinese Academy of Sciences (CAS) is getting into the venture capital business; China will encourage private entities to invest in hospitals and clinics; Shanghai banned three medical device companies for two years because of bribery; Shenzhen Neptunus Bio will raise $219 million to upgrade its distribution network; Guangzhou Pharma Group signed a strategic alliance with Fuyang Municipal Government in Anhui province; ScinoPharm will be the sole manufacturer for the API of a new anti-depressant; and American Oriental Bioengineering named a US CRO to oversee American clinical trials of AOBO drugs. More details….
Stock Symbols: (NYSE: CRL) (XETRA: BAY) (SHE: 000078) (NYSE: AOB)
